Mereo BioPharma (MREO) Total Debt (2017 - 2022)

Mereo BioPharma (MREO) has 6 years of Total Debt data on file, last reported at $13.0 million in Q4 2022.

• Total Debt for Q4 2022 came in at $13.0 million, down 32.94% year-over-year; the trailing twelve-month figure through Dec 2022 was $13.0 million (down 32.94% YoY), and the FY2022 annual result was $13.0 million, down 32.94% from the prior year.
• Total Debt retreated to $13.0 million in Q4 2022 per MREO's latest filing, from $19.4 million in the prior quarter.
• Over five years, Total Debt peaked at $27.6 million in Q4 2018 and troughed at $13.0 million in Q4 2022.
• A 5-year average of $21.5 million and a median of $21.3 million in 2020 frame the typical range for Total Debt.
• The sharpest annual moves came in 2018 and 2022: Total Debt rose 0.34% in 2018, then sank 32.94% in 2022.
• A 5-year view of Total Debt shows it stood at $27.6 million in 2018, then slipped by 4.61% to $26.4 million in 2019, then decreased by 19.18% to $21.3 million in 2020, then slipped by 9.03% to $19.4 million in 2021, then slumped by 32.94% to $13.0 million in 2022.
• Business Quant data shows MREO's Total Debt at $13.0 million in Q4 2022, $19.4 million in Q4 2021, and $21.3 million in Q4 2020.